

**In the Claims**

Claim 1. (Currently amended) An allogeneic immunotherapeutic agent ~~for eliciting an immunological response against prostate cancer, wherein the immunological agent comprises~~ comprising three human prostate cell lines from three different sources, wherein ~~said sources~~ cell lines are selected from the group consisting of:

- (a) normal prostate human ~~tissue~~ PNT-2,
- (b) primary prostate human ~~tissue~~ NIH-1542, and
- (c) ~~metastatic~~ cancerous prostate human ~~tissue~~, LNCap

~~and wherein one to three of said human prostate cell lines is non-cancerous.~~

Claims 2-10. (Canceled).

Claim 11. (Previously presented) An allogeneic immunogenic composition comprising the immunotherapeutic agent of claim 1, combined with a vaccine adjuvant selected from the group consisting of BCG, *M. Vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4, interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant, and non-specific adjuvants.

Claim 12. (Currently amended) An immunogenic composition comprising the immunotherapeutic agent of claim 1, ~~combined with~~ and a vaccine adjuvant, wherein ~~said~~ the adjuvant is a mycobacterial preparation.

Claims 13-24. (Canceled).

Claim 25. (Currently amended) The allogeneic immunotherapeutic agent of claim 1, wherein ~~said~~ the cell lines are selected so as to maximize haplotype mismatch.

Claim 26. (Currently amended) The allogeneic immunotherapeutic agent of claim 1, wherein ~~said~~ the cell lines ~~derived from primary and metastatic prostate human tissue~~ are rendered replication-incompetent by irradiation.